Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD.
Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD.
复制标题
DOI：
10.2147/copd.s104490
复制
发表时间：
2016
影响因子：
2.8
通讯作者：
Morimoto T
中科院分区：
文献类型：
--
作者：
Funamoto M;Sunagawa Y;Katanasaka Y;Miyazaki Y;Imaizumi A;Kakeya H;Yamakage H;Satoh-Asahara N;Komiyama M;Wada H;Hasegawa K;Morimoto T
COPD主要由吸烟引起，并与冠状动脉疾病的高频率相关。越来越多的人认识到，COPD的炎症不仅限于肺部，还涉及体循环，并可能影响非肺部器官，包括血管。α1-抗胰蛋白酶-低密度脂蛋白（AT-LDL）复合物是一种氧化修饰的LDL，可加速动脉粥样硬化。姜黄素是研究最多的天然产物之一，是一种强大的抗氧化剂。然而，姜黄素对AT-LDL的影响仍然未知。我们假设Theracurmin®，一种使用药物递送系统具有改善的生物利用度的高吸收性姜黄素，改善了轻度COPD受试者的炎症状态。这是一项随机、双盲、平行组研究。根据日本呼吸学会标准，患有I-II期COPD的受试者被随机分配接受90 mg Theracurmin®或安慰剂，每天两次，持续24周，并评估炎症参数的变化。Theracurmin®组和安慰剂组在39例可评价受试者的年龄、男女比例或体重指数方面无差异。两组治疗后血压、血红蛋白A1 c和LDL-胆固醇、甘油三酯或高密度脂蛋白-胆固醇水平的百分比变化相似。然而，Theracurmin®组中AT-LDL水平的百分比变化显著（P=0.020）低于安慰剂组。Theracurmin®降低了动脉粥样硬化AT-LDL的水平，这可能导致预防轻度COPD受试者未来的心血管事件。
COPD is mainly caused by tobacco smoking and is associated with a high frequency of coronary artery disease. There is growing recognition that the inflammation in COPD is not only confined to the lungs but also involves the systemic circulation and can impact nonpulmonary organs, including blood vessels. α1-antitrypsin–low-density lipoprotein (AT-LDL) complex is an oxidatively modified LDL that accelerates atherosclerosis. Curcumin, one of the best-investigated natural products, is a powerful antioxidant. However, the effects of curcumin on AT-LDL remain unknown. We hypothesized that Theracurmin®, a highly absorptive curcumin with improved bioavailability using a drug delivery system, ameliorates the inflammatory status in subjects with mild COPD. This is a randomized, double-blind, parallel-group study. Subjects with stages I–II COPD according to the Japanese Respiratory Society criteria were randomly assigned to receive 90 mg Theracurmin® or placebo twice a day for 24 weeks, and changes in inflammatory parameters were evaluated. There were no differences between the Theracurmin® and placebo groups in terms of age, male/female ratio, or body mass index in 39 evaluable subjects. The percent changes in blood pressure and hemoglobin A1c and LDL-cholesterol, triglyceride, or high-density lipoprotein-cholesterol levels after treatment were similar for the two groups. However, the percent change in the AT-LDL level was significantly (P=0.020) lower in the Theracurmin® group compared with the placebo group. Theracurmin® reduced levels of atherosclerotic AT-LDL, which may lead to the prevention of future cardiovascular events in mild COPD subjects.